Pharmacological screening of glibenclamide solid dispersion in fructose-fed diabetic rats

Abstract

Abstract Objectives In this study, our main objective was to estimate the therapeutic effectiveness of the formulated solid dispersion of glibenclamide (GSD) with improved dissolution profiles in comparison with pure glibenclamide (GLB) by means of a fructose-fed diabetic rat model. Methods To evaluate the pharmacological effectiveness of the formulated GSD, a fructose-fed diabetic rat model evolved and the obtained consequences were compared with the conventional GLB treatment. Key findings GSD exhibited improved glucose and lipid-lowering efficacy of GSD in contrast to pure GLB after 15 days of treatment. Low dose (0.5 mg/kg) and high dose (5 mg/kg) of GSD showed significant lowering of blood glucose which is 6 ± 0.2 mmol/L and 5.6 ± 0.3 mmol/L respectively after 15 days of treatment is much better than that of pure GLB (6.2 ± 0.4 mmol/L). Furthermore, low dose of GSD presented approximately comparable beneficiary effects in regard to triglycerides (72.00 ± 7.23 mg/dL), total cholesterol (110.33 ± 5.78 mg/dL), low-density lipoprotein (67.60 ± 5.21 mg/dL) and high-density lipoprotein (28.33 ± 1.53 mg/dL) as pure GLB after 15 days. Additionally, histological studies as well confirmed no fatty infiltration from the liver by GSD as compared with GLB which was consistent with the biochemical parameters. Conclusions For treating diabetes and hyperlipidaemia, the formulated GSD might be a potential substitute for traditional GLB.